This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval For Its Phase III Clinical Trial Protocol; Phase III Clinical Trial To Begin In 3Q 2013

SAN DIEGO, July 22, 2013 /PRNewswire/ --  Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor™. Imprimis has engaged Agility Clinical, Inc., a Carlsbad, CA-based consulting and contract research organization (CRO), to conduct the study at 20 - 30 US sites. The IRB-approved Phase III trial is a randomized, multicenter, double-blind, parallel-group study to assess the efficacy and safety of Impracor (ketoprofen 10% cream) compared with placebo in the treatment of acute pain (flare) associated with osteoarthritis (OA) of the knee.

As previously announced, Imprimis designed the Phase III study with the assistance of key opinion leaders, and also relied upon feedback from the U.S. Food and Drug Administration (FDA) following a Type C meeting between Imprimis and FDA officials in April 2013.

"This is an important and critical step forward for Imprimis as we prepare to start enrollment of our Phase III clinical trial in the third quarter of this year," said Imprimis CEO Mark L. Baum. "The IRB approval of this protocol in many ways represents the culmination of a year of hard work, and marks the initiation of our Impracor Phase III study. With Agility as our clinical operations team, we have an experienced partner that will help us bring forward a new alternative therapy in the space of anti-inflammatory, pain-relieving drugs, to improve patient health and quality of life. We are delighted to be working with Dr. Neil Singla of Lotus Clinical Research, who has an excellent track record in conducting successful trials in the pain sector."

"We are excited that the Imprimis Phase III protocol was approved by an independent central ethics committee, Schulman Associates Institutional Review Board, Inc.," said Imprimis Chief Medical Officer Dr. Joachim Schupp. "This is an important milestone to commence our Phase III study in the third quarter of this year. The primary role of an IRB is to safeguard the rights, safety and welfare of participants in research. Agility Clinical and Lotus Clinical Research were instrumental in the final protocol and informed consent preparation."

"Helping innovative companies bring new treatments to patients is an important part of Agility's mission," said Ellen Morgan, CEO of Agility Clinical. "We are excited to be working with Imprimis and Lotus Clinical Research on this study. If approved, Impracor will provide patients suffering from osteoarthritis of the knee with an alternative to systemic NSAIDs for the management of their pain."

"We appreciate the opportunity to work with Imprimis Pharmaceuticals, Inc. and Agility Clinical on this important clinical trial," said Dr. Neil Singla, Owner of Lotus Clinical Research. "All parties have worked diligently over the past several months to design a robust protocol that will answer many critical regulatory and therapeutic questions concerning Impracor."

Imprimis has commenced the investigational site selection for training, qualification and study initiation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,807.53 +31.10 0.19%
S&P 500 1,983.37 -3.68 -0.19%
NASDAQ 4,752.5210 -28.7430 -0.60%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs